CGTNXinjiang in its most prosperous period ever: white paper
BEIJING, Sept. 20, 2025 /PRNewswire/ -- Today's Xinjiang is experiencing the best period…
Nxera Pharma and Cancer Research UK Announce First Patient Dosed in Phase 2a Trial of Investigational Cancer Immunotherapy HTL0039732
HTL0039732 (also known as NXE0039732) is Nxera’s novel oral EP4 antagonist being…
South Africa’s automotive industry: Overcoming challenges
The automotive industry is one of the most important economic sectors in…
Silicon Motion to Attend Upcoming Investor Conferences
TAIPEI, Taiwan and MILPITAS, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Silicon Motion Technology…
Automobili Lamborghini confirms strong financial performance in the first half of 2025
The new hybrid range demonstrates the effectiveness of the Sant’Agata Bolognese company’s…
Hexaware Delivers Solid Q2CY25 Revenue of USD 382.1 Mn, Up 8.6% YoY
Q2CY25 EBITDA Expansion of 156 bps YoY Q2CY25 EPS at INR 6.25…
Shopware Reports Exponential Growth in North America for the First Half of 2025
Credits surge to the addition of flagship clients and solid expansion of…
Euroclear reports robust H1 2025 results
BRUSSELS, July 18, 2025 /PRNewswire/ -- Results for the first half year…
Instil Bio Announces U.S. F.D.A. Clearance of Investigational New Drug (IND) Application for AXN-2510, a PD-L1xVEGF Bispecific Antibody, for a Phase 1 Trial in Relapsed/Refractory Solid Tumors
July 02, 2025 06:00 ET | Source: Instil Bio US phase 1…